Clinical profile and challenges faced in the management of optic neuritis: the Indian scenario

Int Ophthalmol. 2024 Mar 15;44(1):138. doi: 10.1007/s10792-024-03081-1.

Abstract

Purpose: Optic neuritis (ON) is a relatively common ophthalmic disease that has recently received renewed attention owing to immunological breakthroughs. We studied the profile of patients with ON with special reference to antibody-mediated ON and the challenges faced in its management.

Methods: Case records of patients with ON presenting to a tertiary eye-care center in South India were analyzed. Data on demographics, presenting visual acuity (VA), clinical features, seropositivity for aquaporin-4 immunoglobulin G (AQP4-IgG) and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG), details of magnetic resonance imaging (MRI) of orbits and brain, and treatment were collected.

Results: Among 138 cases with acute ON, male: female ratio was 1:2. Isolated ON was present in 41.3% of cases. Antibody testing of sera was performed in 68 patients only due to financial limitations. Among these, 48.5% were MOG-IgG-seropositive, 11.76% were AQP4-IgG-seropositive, and 30.88% samples were double seronegative. Other causes included multiple sclerosis (n = 4), lactational ON (n = 4), tuberculosis (n = 2), invasive perineuritis (n = 2), COVID-19 vaccination (n = 2), and COVID-19 (n = 1). The mean presenting best corrected visual acuity (BCVA) was 1.31 ± 1.16 logMAR (logarithm of the minimum angle of resolution). The mean BCVA at 3 months was 0.167 ± 0.46 logMAR. Only initial VA ≤ 'Counting fingers' (CF) had a significant association with the visual outcome for final VA worse than CF. The steep cost of investigations and treatment posed challenges for many patients in the management of ON.

Conclusion: MOG-IgG-associated ON is common in India. Unfortunately, financial constraints delay the diagnosis and timely management of ON, adversely affecting the outcome.

Keywords: AQP4-IgG-associated optic neuritis; Atypical optic neuritis; Double seronegative optic neuritis; MOG-IgG-associated optic neuritis; Neuromyelitis optica spectrum disorder; Optic neuritis.

MeSH terms

  • Aquaporin 4 / therapeutic use
  • Autoantibodies / therapeutic use
  • COVID-19 Vaccines / therapeutic use
  • COVID-19*
  • Female
  • Humans
  • Immunoglobulin G / therapeutic use
  • Male
  • Neuromyelitis Optica*
  • Optic Neuritis* / drug therapy
  • Optic Neuritis* / therapy

Substances

  • COVID-19 Vaccines
  • Autoantibodies
  • Aquaporin 4
  • Immunoglobulin G